title: The G(2) checkpoint is maintained by redundant pathways.
abstract: While p53 activity is critical for a DNA damage-induced G(1) checkpoint, its role in the G(2) checkpoint has not been compelling because cells lacking p53 retain the ability to arrest in G(2) following DNA damage. Comparison between normal human foreskin fibroblasts (HFFs) and HFFs in which p53 was eliminated by transduction with human papillomavirus type 16 E6 showed that treatment with adriamycin initiated arrest in G(2) with active cyclin B/CDC2 kinase, regardless of p53 status. Both E6-transduced HFFs and control (LXSN)-transduced cells maintained a prolonged arrest in G(2); however cells with functional p53 extinguished cyclin B-associated kinase activity. Down regulation was mediated by p53-dependent transcriptional repression of the CDC2 and cyclin B promoters. In contrast, cells lacking p53 showed a prolonged G(2) arrest despite high levels of cyclin B/CDC2 kinase activity, at least some of which translocated into the nucleus. Furthermore, the G(2) checkpoint became attenuated as p53-deficient cells aged in culture. Thus, at late passage, E6-transduced HFFs entered mitosis following DNA damage, whereas the age-matched parental HFFs sustained a G(2) arrest. These results indicate that normal cells have p53-independent pathways to maintain DNA damage-induced G(2) arrest, which may be augmented by p53-dependent functions, and that cells lacking p53 are at greater risk of losing the pathway that protects against aneuploidy.
authors.affiliation: Program in Cancer Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109-1024, USA.
authors.forename: T M
authors.initials: TM
authors.lastname: Passalaris
authors.forename: J A
authors.initials: JA
authors.lastname: Benanti
authors.forename: L
authors.initials: L
authors.lastname: Gewin
authors.forename: T
authors.initials: T
authors.lastname: Kiyono
authors.forename: D A
authors.initials: DA
authors.lastname: Galloway
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology; D016203:CDC2 Protein Kinase / Q000235:genetics / Q000378:metabolism; D002478:Cells, Cultured; D019926:Cyclin B / Q000235:genetics / Q000378:metabolism; D004249:DNA Damage; D015536:Down-Regulation; D004317:Doxorubicin / Q000494:pharmacology; D005347:Fibroblasts / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D016195:G2 Phase / Q000187:drug effects / Q000235:genetics / Q000502:physiology*; D016158:Genes, p53; D006801:Humans; D008297:Male; D051379:Mice; D018345:Mice, Knockout; D027383:Papillomaviridae / Q000235:genetics; D013347:Subcellular Fractions / Q000378:metabolism; D014170:Transformation, Genetic
chemical_list: D000970:Antineoplastic Agents; D019926:Cyclin B; D004317:Doxorubicin; D016203:CDC2 Protein Kinase